Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Am J Physiol Heart Circ Physiol ; 287(6): H2478-86, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15284071

RESUMEN

Cardiac fibroblasts (CF) express adenosine (ADO) receptors, and pharmacological evidence suggests the possible involvement of the A2 (A2a and A2b) receptor (A2aR and A2bR) subtypes in inhibiting cell functions involved in fibrosis. The main objective of this study was to define the contributions of A2a and/or A2b receptors in modulating ADO-induced decreases in CF functions. For this purpose, CF were either treated pharmacologically or had the A2aR or A2bR levels modified through the use of recombinant adenovirus or siRNA. The assessment of mRNA expression in adult rat CF yielded evidence for A1R, A2bR, A2a), and A3R. Endogenously or exogenously enhanced ADO significantly inhibits CF proliferation, collagen, and protein synthesis. A2R and A2aR agonists, although capable of inhibiting CF protein and collagen synthesis, were unable to define the contributions derived from A2aR or A2bR. Overexpression of A2bR in CF yielded significant decreases in basal levels of collagen and protein synthesis and correlated with increases in cAMP levels. However, at higher doses of ADO receptor agonists, significant increases in protein and collagen synthesis were observed. CF with underexpression of A2bR yielded increases in protein and collagen synthesis. In contrast, A2aR underexpression did not modify ADO-induced decreases in CF protein or collagen synthesis. In conclusion, results derived from the molecular manipulation of receptor levels indicate that A2bR are critically involved in ADO-mediated inhibition of CF functions.


Asunto(s)
Fibroblastos/metabolismo , Miocardio/metabolismo , Receptor de Adenosina A2B/genética , Receptor de Adenosina A2B/metabolismo , 2-Cloroadenosina/farmacología , Adenosina Quinasa/antagonistas & inhibidores , Adenosina-5'-(N-etilcarboxamida)/farmacología , Animales , División Celular/fisiología , Células Cultivadas , Colágeno/biosíntesis , Colágeno/metabolismo , AMP Cíclico/metabolismo , Matriz Extracelular/metabolismo , Fibroblastos/citología , Expresión Génica , Silenciador del Gen , Ventrículos Cardíacos/citología , Leucina/farmacocinética , Masculino , Miocardio/citología , Ratas , Ratas Sprague-Dawley , Receptor de Adenosina A2A/genética , Receptor de Adenosina A2A/metabolismo , Timidina/farmacocinética , Tritio , Vasodilatadores/farmacología
2.
Mol Cell Biochem ; 251(1-2): 17-26, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-14575299

RESUMEN

The increasing incidence of congestive heart failure has stimulated efforts to develop pharmacologic strategies to prevent or reverse the associated process of adverse cardiac remodeling. The possibility of utilizing endogenously generated factors that are capable of inhibiting this process is beginning to be explored. Adenosine, has been described as a retaliatory autacoid with homeostatic activities in the regulation of myocardial blood flow, catecholamine release, and reduction of injury resulting from periods of ischemia. Adenosine exerts a variety of actions that are consistent with the concept that it can reduce or inhibit the process of cardiac remodeling. In this manuscript, the basics of adenosine metabolism, its cell surface receptors and beneficial actions on the cardiovascular system are reviewed. In addition new, in vitro and in vivo data will be presented supporting the concept that adenosine exerts actions that may ameliorate adverse cardiac remodeling.


Asunto(s)
Adenosina/metabolismo , Adenosina/uso terapéutico , Infarto del Miocardio/tratamiento farmacológico , Remodelación Ventricular/fisiología , Animales , Sistema Cardiovascular/metabolismo , Humanos , Técnicas In Vitro , Modelos Biológicos , Isquemia Miocárdica/tratamiento farmacológico , Daño por Reperfusión Miocárdica/prevención & control , Receptores Purinérgicos P1/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Remodelación Ventricular/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA